According to MiBiz, Drug developer Tetra Discovery Partners has closed on $5 million in new venture capital funding.

The Apjohn Group in Kalamazoo and Holland-based Grand Angels led the investment with San Francisco-based venture firm Dolby Family Ventures. The closing elevated a Series A financing for Tetra Discovery to $7.27 million.

Tetra is developing a platform of drug products to treat cognitive impairment. Tetra drugs target a family of related enzymes known as Type 4 phosphodiesterases (PDE4). The lead drug targeting PDE4D is being developed for treating cognitive impairment in Alzheimer's disease or schizophrenia with potential applications for Huntington's disease, Fragile X syndrome, autism, and major depression. Rather than addressing a specific chemical deficit or dysfunction in a specific neural circuit, targeting PDE4D has the potential to augment the fundamental processes underlying learning and memory in the human brain, thereby allowing compensatory brain mechanisms to improve function in the diseased brain.